Synthesis, Structural Properties and Biological Activities of Novel Hydrazones of 2-, 3-, 4-Iodobenzoic Acid.
Hydrazones
/ chemistry
Humans
Microbial Sensitivity Tests
Anti-Bacterial Agents
/ pharmacology
Iodobenzoates
/ chemistry
Antineoplastic Agents
/ pharmacology
Molecular Structure
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Crystallography, X-Ray
Structure-Activity Relationship
Anti-Infective Agents
/ pharmacology
acylhydrazones
antimicrobial activity
bioactivity
crystal structure
cytotoxicity
iodobenzoic acid derivatives
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
11 Aug 2024
11 Aug 2024
Historique:
received:
29
05
2024
revised:
30
07
2024
accepted:
02
08
2024
medline:
1
9
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Nowadays, searching for novel antimicrobial agents is crucial due to the increasing number of resistant bacterial strains. Moreover, cancer therapy is a major challenge for modern medicine. Currently used cytostatics have a large number of side effects and insufficient therapeutic effects. Due to the above-mentioned facts, we undertook research to synthesize novel compounds from the acylhydrazone group aimed at obtaining potential antimicrobial and anticancer agents. As a starting material, we employed hydrazides of 2-, 3- or 4-iodobenzoic acid, which gave three series of acylhydrazones in the condensation reaction with various aldehydes. The chemical structure of all obtained compounds was confirmed by IR,
Identifiants
pubmed: 39202893
pii: molecules29163814
doi: 10.3390/molecules29163814
pmc: PMC11356900
pii:
doi:
Substances chimiques
Hydrazones
0
Anti-Bacterial Agents
0
Iodobenzoates
0
Antineoplastic Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Molecules. 2017 Sep 01;22(9):
pubmed: 28862683
Molecules. 2017 Apr 19;22(4):
pubmed: 28422067
Int J Mol Sci. 2023 Dec 14;24(24):
pubmed: 38139308
Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):3-8
pubmed: 25567568
Microb Pathog. 2016 Sep;98:1-5
pubmed: 27334293
Drug Dev Res. 2016 Nov;77(7):379-392
pubmed: 27775155
Molecules. 2007 Aug 17;12(8):1910-39
pubmed: 17960096
J Appl Crystallogr. 2020 Feb 01;53(Pt 1):226-235
pubmed: 32047413
Med Chem Res. 2017;26(2):287-301
pubmed: 28163562
Bioorg Chem. 2020 Aug;101:104014
pubmed: 32599364
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
Chem Rev. 2014 Feb 26;114(4):2170-91
pubmed: 24350653
Bioorg Med Chem. 2014 Sep 1;22(17):4629-36
pubmed: 25127462
J Enzyme Inhib Med Chem. 2016;31(sup1):62-69
pubmed: 27075005
Int J Antimicrob Agents. 2010 Jan;35(1):30-8
pubmed: 19748233
Biomed Pharmacother. 2020 Oct;130:110526
pubmed: 32693180
ACS Omega. 2020 Jun 23;5(26):15805-15811
pubmed: 32656400
Heliyon. 2020 Sep 29;6(9):e05019
pubmed: 33024857
Biomed Pharmacother. 2022 Sep;153:113302
pubmed: 35724512
Acta Crystallogr B. 2007 Dec;63(Pt 6):879-95
pubmed: 18004043
Pharmaceutics. 2022 Oct 24;14(11):
pubmed: 36365097
Molecules. 2023 Jul 07;28(13):
pubmed: 37446945
J Mol Evol. 2020 Jan;88(1):26-40
pubmed: 31659373
RSC Adv. 2020 Oct 20;10(63):38566-38577
pubmed: 35517547
Molecules. 2020 Jun 11;25(11):
pubmed: 32545272
Chem Commun (Camb). 2016 Jun 14;52(50):7760-81
pubmed: 27185190
ADMET DMPK. 2022 Jan 12;10(2):163-179
pubmed: 35350113